The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, ...

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing ...

The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

The U.S. Food and Drug Administration said a comprehensive review “found no increased” risk related to suicide among users of ...

FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...

When people who are overweight and obese stopped taking their weight-loss medications they regained weight faster than those ...

Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal ...

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk’s Wegovy and ...

A fascinating deep dive into the discovery, use and implications of a revolutionary new treatment ...

The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior. ・The ...

Research has shown that people who stop taking GLP-1 drugs, such as Ozempic and Wegovy, typically experience weight regain ...